RT Journal Article
T1 Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma
A1 Puig, Noemí
A1 Flores Montero, Juan
A1 Burgos, Leire
A1 Cedena Romero, M. Teresa
A1 Cordón, Lourdes
A1 Pérez, José Juan
A1 Sanoja Flores, Luzalba
A1 Manrique, Irene
A1 Rodríguez Otero, Paula
A1 Rosiñol, Laura
A1 Martínez López, Joaquín
A1 Mateos, María Victoria
A1 Lahuerta, Juan José
A1 Bladé, Joan
A1 San Miguel, Jesús F.
A1 Orfao, Alberto
A1 Paiva, Bruno
AB Background: Whereas, in most patients with multiple myeloma (MM), achieving undetectable MRD anticipates a favorable outcome, some others relapse shortly afterwards. Although one obvious explanation for this inconsistency is the use of nonrepresentative marrow samples due to hemodilution, there is no guidance on how to evaluate this issue. Methods: Since B-cell precursors, mast cells and nucleated red blood cells are normally absent in peripheral blood, we analyzed them in 1404 bone marrow (BM) aspirates obtained in numerous disease settings and in 85 healthy adults (HA). Results: First, we confirmed the systematic detection of the three populations in HA, as well as the nonreduced numbers with aging. Pairwise comparisons between HA and MM patients grouped according to age and treatment showed significant variability, suggesting that hemodilution should be preferably evaluated with references obtained from patients treated with identical regimens. Leveraging the MRD results from 118 patients, we showed that a comparison with HA of similar age could also inform on potential hemodilution. Conclusions: Our study supports the routine assessment of BM cellularity to evaluate hemodilution, since reduced BM-specific cell types as compared to reference values (either treatment-specific or from HA if the former are unavailable) could indicate hemodilution and a false-negative MRD result.
PB MDPI
SN 2072-6694
YR 2021
FD 2021-09-25
LK https://hdl.handle.net/20.500.14352/5049
UL https://hdl.handle.net/20.500.14352/5049
LA eng
NO Puig N, Flores-Montero J, Burgos L, Cedena M-T, Cordón L, Pérez J-J, et al. Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma. Cancers 2021;13:4924. https://doi.org/10.3390/cancers13194924.
NO This study was supported by grants from the Centro de Investigación Biomédica en Red—Área de Oncología—del Instituto de Salud Carlos III (CIBERONC; CB16/12/00369, CB16/12/00400, CB16/12/00233 and CB16/12/00284); Instituto de Salud Carlos III/Subdirección General de Investigación Sanitaria and co-financed by FEDER funds (FIS No. PI15/01956, PI15/02049, PI15/02062, PI18/01709, PI18/01673 and PI19/01451); the Cancer Research UK (C355/A26819), FCAECC and AIRC under the Accelerator Award Programme (EDITOR); the Black Swan Research Initiative of the International Myeloma Foundation and the European Research Council (ERC) 2015 Starting Grant (Contract 680200 MYELOMANEXT). This study was supported by the Riney Family Multiple Myeloma Research Program Fund.
NO Unión Europea
NO Consejo Europeo de Investigación
NO Centro de Investigación Biomédica en Red
NO Instituto de Salud Carlos III
NO Cancer Research UK
NO The Italian Foundation for Cancer Research
NO Fundación Internacional del Mieloma
NO Asociación Española contra el Cáncer
DS Docta Complutense
RD 7 abr 2025